Treatment of diffuse malignant mesothelioma: A review

A. P. Chahinian, J. F. Holland

Research output: Contribution to journalReview articlepeer-review

41 Scopus citations


Epidemiologic studies have anticipated an increase in incidence of malignant mesothelioma in the next decades, largely due to the wide utilization of asbestos. A thorough literature survey has been made of therapeutic modalities presumably available. In the series reviewed the prognosis is usually poor, whatever the treatment. Surgery can relieve temporarily such distressing symptoms as pain or recurrent pleural effusion. Radiotherapy, by conventional or high dose procedures, has led to partial control in some series, but not in others. Many different chemotherapies have been applied in small series of patients. Presently, adriamycin seems to be the most promising single agent. Local therapies are of little value. Controlled therapeutic trials are needed for more precise information about the treatment of this neoplasm.

Original languageEnglish
Pages (from-to)54-67
Number of pages14
JournalMount Sinai Journal of Medicine
Issue number1
StatePublished - 1978
Externally publishedYes


Dive into the research topics of 'Treatment of diffuse malignant mesothelioma: A review'. Together they form a unique fingerprint.

Cite this